Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Neurological Medicine
Volume 2015 (2015), Article ID 892047, 4 pages
http://dx.doi.org/10.1155/2015/892047
Case Report

Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan

Department of Neurology, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03766, USA

Received 7 October 2014; Revised 7 January 2015; Accepted 15 January 2015

Academic Editor: Jacqueline A. Pettersen

Copyright © 2015 Michael A. Lane et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Warnke, M. Stettner, V. Lehmensiek et al., “Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF,” Multiple Sclerosis Journal, 2014. View at Publisher · View at Google Scholar
  2. S. Warsch, P. J. Hosein, M. I. Morris et al., “Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab,” International Journal of Hematology, vol. 96, no. 2, pp. 274–278, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. K. R. Carson, D. Focosi, E. O. Major et al., “Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) Project,” The Lancet Oncology, vol. 10, no. 8, pp. 816–824, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. T. E. Witzig, “Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma,” Drugs of Today, vol. 40, no. 2, pp. 111–119, 2004. View at Publisher · View at Google Scholar
  5. N. Tageja, “Bendamustine: safety and efficacy in the management of indolent non-Hodgkins lymphoma,” Clinical Medicine Insights: Oncology, vol. 5, pp. 145–156, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J. R. Berger, S. A. Houff, J. Gurwell, N. Vega, C. S. Miller, and R. J. Danaher, “JC virus antibody status underestimates infection rates,” Annals of Neurology, vol. 74, no. 1, pp. 84–90, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Warnke, G. von Geldern, P. Markwerth et al., “Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy,” Annals of Neurology, vol. 76, no. 6, pp. 792–801, 2014. View at Publisher · View at Google Scholar
  8. T. Plavina, M. Subramanyam, G. Bloomgren et al., “Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy,” Annals of Neurology, vol. 76, no. 6, pp. 802–812, 2014. View at Publisher · View at Google Scholar